Cell line · CVCL_1902
WSU-DLCL2
Cancer cell line, Homo sapiens. Diffuse large B-cell lymphoma germinal center B-cell type. 34 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. WSU-DLCL2. Cell lines, record CVCL_1902. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1902
On this page
Cell line
As Cellosaurus gives it.
- Name
- WSU-DLCL2
- Accession
- CVCL_1902
- RRID
- RRID:CVCL_1902
- Synonyms
- WSU-DLCL-2, WSU-DLCL(2), WSUDLCL2
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 41Y
- Category
- Cancer cell line
- Diseases
- Diffuse large B-cell lymphoma germinal center B-cell type (NCIt C36080); Diffuse large B-cell lymphoma (ORDO Orphanet_544)
- Derived from
- Pleural effusion (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers34
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DNA Hypomethylating Agents Preserve T-cell Stemness and Potentiate the Efficacy of CD3-Bispecific Antibodies. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Growth Supporting Role of ZDHHC11 Is Linked to the MEF2B-BCL6 Regulatory Circuit in Burkitt Lymphoma. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hi-C for genome-wide detection of enhancer-hijacking rearrangements in routine lymphoid cancer biopsies. | Cell Genom | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. | Blood Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| EZB-type diffuse large B-cell lymphoma cell lines have superior migration capabilities compared to MCD-type. | Br J Haematol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. | Cancer Discov | 2023 | Its Methods give the RRID and name the line | PubMed | |
| IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 34
See all 34 papersRelatives0
None in this release.
Cell banks1
| Cell bank | Catalog number | Status |
|---|---|---|
| DSMZ | ACC-575 |
Source DSMZ
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1902
GET https://conductscience.org/api/cell-lines/v1/CVCL_1902/papers?page=2